UPDATE : Thursday, August 6, 2020
HOME Pharma
Hugel names new CEO of its US offshoot
  • By Lee Han-soo
  • Published 2020.05.12 17:32
  • Updated 2020.05.12 17:38
  • comments 0

Hugel said Monday that it has appointed James P. Hartman as the new CEO of Hugel America, its subsidiary for North America. New CEO Hartman has extensive experience and knowledge in the medical aesthetics space, the company said.

James P. Hartman, new CEO of Hugel America

Hartman joins Hugel America after serving as the COO of Alastin Skincare, a derma cosmetics company. While at Alastin, he served as an integral member in leading the company to market-leading growth and increased revenues by more than 250 percent.

Before joining Alastin Skincare, he worked at Merz Aesthetics, a division of Merz North America, as its vice president. He also worked at Obagi, Stiefel, and Allergan.

Hartman participated in the launch of the world's first botulinum toxin product, Botox, and developed portfolio strategy that combines botulinum toxin, medical devices and skincare products during his stint at Merz North America.

"James Hartman is a seasoned expert in the medical aesthetic field with abundant commercial experiences and proven track record of building differentiated brands," Hugel CEO Sohn Ji-hoon said. "We are excited to work with him to launch Hugel's products in the U.S., Canada and Australia through innovative and strategic approaches."

Hugel established Hugel America jointly with Croma Pharma, an Austrian-based pharmaceutical company, to serve as its marketing base in North America, Australia and New Zealand.

The company plans to submit the biologics license application (BLA) to the U.S. Food and Drug Administration by the end of this year and expects to obtain final approval by the end of next year.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top